Brief: Jazz Pharmaceuticals To Showcase New Real-World Evidence Reinforcing Epidiolex® (Cannabidiol) Benefits
06/12/2024 21:37
Dec 6 (Reuters) - Jazz Pharmaceuticals PLC JAZZ.O :
* JAZZ PHARMACEUTICALS TO SHOWCASE NEW REAL-WORLD EVIDENCE
REINFORCING EPIDIOLEX® (CANNABIDIOL) BENEFITS AND BROAD-SPECTRUM
EFFICACY IN TREATMENT-RESISTANT EPILEPSIES AT THE AMERICAN
EPILEPSY SOCIETY 2024 ANNUAL MEETING
Source text: ID:nPn26BFwVa
Further company coverage: JAZZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jazz Pharmaceuticals
See all newsBrief: Jazz Pharmaceuticals Enters Amendment No. 4 To Credit Agreement On Sept 23, 2026
U.S. STOCKS ON THE MOVE-BWX Technologies, Synopsys,Burlington Stores
U.S. STOCKS ON THE MOVE-Jazz Pharmaceuticals, Celularity, Infleqtion
Jazz Pharma dips after upsized $1.1 bln convertible offering
Brief: Jazz Pharmaceuticals Announces Private Offering Of $1.0 Billion Of Exchangeable Senior Notes Due 2032